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Strengths and limitations of this study
 ► There has been a longstanding debate about the 
efficacy of transcutaneous electrical nerve stimula-
tion (TENS) because systematic reviews for specific 
medical conditions have been inconclusive due to 
insufficient data.
 ► This protocol defines a systematic review with me-
ta-analysis of randomised controlled clinical trials to 
evaluate the clinical efficacy and safety of TENS for 
any type of acute and chronic pain in adults.
 ► The main strength of this protocol is the assessment 
of TENS on pain associated with a variety of condi-
tions and this will provide clinicians, policy-makers, 
and patients with a source of information on the ef-
fects of TENS for any type of pain.
 ► The main concern of this protocol is that the variety 
of types of pain and types of TENS interventions has 
potential for clinical and statistical heterogeneity.
 ► This concern will be managed by conducting 
preplanned subgroup analyses of specific med-
ical conditions based on International Statistical 
Classification of Diseases and Related Health 
Problems-11th Revision categories, and optimal 
TENS techniques.
ABSTRACT
Introduction The aim of this systematic review with 
meta-analysis is to evaluate the clinical efficacy of 
transcutaneous electrical nerve stimulation (TENS) for any 
type of acute and chronic pain in adults.
Methods and analysis We intend to search electronic 
databases (Cochrane Library, MEDLINE, Embase, CINAHL, 
PsycINFO, LILACS, PEDRO, Web of Science, AMED and 
SPORTDiscus) from inception to the present day to identify 
all randomised controlled trials (RCT) on the use of TENS 
in adults for any type of pain including acute pain, chronic 
pain and cancer-related pain. We will screen the RCTs 
against eligibility criteria for inclusion in our review. Two 
reviewers will independently undertake RCT selection, 
data extraction and risk of bias assessment. Primary 
outcomes will be: (i) participant-reported pain relief 
of ≥30% expressed as frequency (dichotomous) data; 
and (ii) participant-reported pain intensity expressed as 
mean (continuous) data. We will conduct meta-analyses 
to determine risk ratio for dichotomous data, and mean 
difference (MD) or standardised MD for continuous data 
for TENS versus placebo TENS, no treatment or waiting list 
control, standard of care, and other treatments. Subgroup 
analyses will include different pain conditions (eg, acute 
vs chronic), TENS intensity, during versus after TENS, TENS 
as a sole treatment versus TENS in combination with other 
treatments and TENS administered as a single dose versus 
repetitive dose.
Ethics and dissemination This systematic review will 
not use data from individual participants, and the results 
will be disseminated in a peer-reviewed publication and 
presented at a conference.
PROSPERO registration number CRD42019125054.
InTROduCTIOn
Pain is a major healthcare issue. Estimates of 
the prevalence of acute pain in adults suggest 
that it may be as high as 70.7% in accident and 
emergency departments and 50% in hospital 
inpatients, with up to 35% of patients reporting 
severe pain.1 Estimates of the worldwide prev-
alence of chronic pain in the general adult 
population suggest it may affect up to 45% 
of people, with up to 15% reporting severe 
disabling pain.2–6 Pain is financially expensive 
in terms of medical consultations, treatments 
and time lost from work, and socially expen-
sive in terms of suffering and impaired quality 
of life.7 8 Gaskin and Richard7 estimated that 
annual costs related to healthcare and loss of 
worker productivity in the USA was between 
US$560 and US$635 billion. This was 
greater than heart disease (US$309 billion), 
cancer (US$243 billion), and diabetes 
(US$188 billion). In Europe, Breivik et al9 esti-
mated the national healthcare and socioeco-
nomic costs of chronic pain to be 3%–10% of 
gross domestic product.
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Approximately 40% of people living with chronic pain 
report inadequate pain management and over 60% 
report that medication does not adequately control 
pain.10 Desirable pain-management strategies adopt a 
biopsychosocial approach using pharmacological and 
non-pharmacological interventions tailored to the indi-
vidual. The goal of treatment is to relieve pain and 
improve physiological functioning associated with activ-
ities of daily living, role functioning associated with jobs 
and hobbies, and emotional, cognitive and social func-
tioning associated with quality of life. Early pain manage-
ment is critical to reduce the likelihood of acute pain 
developing into chronic pain. Transcutaneous electrical 
nerve stimulation (TENS) has been used across the 
world for the management of acute and chronic pain 
irrespective of cause, including pain related to cancer 
and its treatment.11
description of the intervention
TENS is the delivery of pulsed electrical currents across the 
intact surface of the skin to stimulate peripheral nerves, 
principally for pain relief.11 TENS may be self-adminis-
tered by the patient, ideally following instruction from 
a healthcare practitioner using a portable, battery-pow-
ered TENS device to produce electrical currents that 
are delivered to the body using self-adhesive electrodes 
attached to the surface of the skin. TENS is available 
without a prescription, is inexpensive and has a good 
safety profile compared with medication.11 Contraindica-
tions include patients who also have cardiac pacemakers 
and implantable cardioverter defibrillators. Precautions 
include pregnancy, epilepsy, active malignancy, deep-vein 
thrombosis and frail or damaged skin.12 13 Two techniques 
are commonly used: conventional TENS administered to 
produce a strong non-painful TENS sensation at the site 
of pain and acupuncture-like TENS to produce strong 
non-painful pulsate sensations, often accompanied by 
muscle twitching.11 Evidence suggests that currents 
with pulse amplitudes (mA) that generate a strong, 
non-painful TENS sensation are critical for response 
and therefore pulse amplitude should be titrated during 
treatment to maintain this intensity level.14–16 There has 
been a longstanding debate about the efficacy of TENS. 
Some clinical guidelines recommend TENS as an adjunct 
to core treatment whereas others do not (for review see 
refs 12 17).
How the intervention might work
In 1965, Melzack and Wall18 proposed that TENS 
could stimulate low-threshold cutaneous afferents to 
inhibit onward transmission of nociceptive informa-
tion in the central nervous system and thus, alleviate 
pain (ie, segmental modulation).19 20 In addition, 
TENS could stimulate small-diameter afferents to acti-
vate descending pain inhibitory pathways21–23 or block 
afferent activity in peripheral neurons, creating a ‘busy-
line’ effect.24
Previous reviews
There is a plethora of systematic reviews on TENS for 
specific conditions and most are inconclusive (for review 
see17 25). An overview of Cochrane reviews provides tenta-
tive evidence that TENS reduces pain intensity when 
administered as a stand-alone treatment for acute pain 
in adults.26 A meta-analysis found the superiority of 
TENS over placebo for reducing postoperative analgesic 
consumption when administered using a strong, subnox-
ious intensity and adequate frequency.14 A Cochrane 
review to assess the effects of TENS on pain during labour 
found limited evidence of effect but concluded women 
should have the choice of using TENS.27
In 2008, a Cochrane review on TENS for chronic pain 
was inconclusive28 although this review has now been 
withdrawn. An overview of Cochrane reviews on TENS for 
chronic pain included a descriptive analysis of 9 reviews 
and 51 RCTs but did not pool data for meta-analyses.29 It 
was not possible to conclude whether TENS was beneficial 
or harmful.29 Most Cochrane reviews on specific chronic 
pain conditions are inconclusive (eg, osteoarthritis of 
the knee,30 neuropathic pain,31 chronic low back pain,32 
cancer pain,33 and phantom pain and stump pain).34 
Interestingly, non-Cochrane reviews with meta-analyses 
have found the superiority of TENS over placebo for 
chronic musculoskeletal pain35 and osteoarthritis of the 
knee.36
Systematic reviews and meta-analyses are hindered by 
methodological weaknesses of included RCTs. Bennett 
et al37 harvested RCTs from Cochrane reviews on TENS 
for acute pain, chronic pain and cancer-related pain and 
found that inadequate method of randomisation, small 
sample sizes and issues associated with the implemen-
tation of a sham (placebo) control such as allocation 
concealment and blinding contributed to an overestima-
tion of TENS effects. The design of an authentic placebo 
control is a challenge. Credible sham TENS devices have 
been used that are identical in appearance to real TENS 
devices and deliver no current or deliver stimulation at 
the start of treatment and fade to zero current output over 
a brief period of time (eg, within 45 s).38 It is not possible 
to blind participants to TENS sensation. Nevertheless, 
uncertainty about allocation to active and inactive TENS 
can be achieved by informing participants that some types 
of electrical stimulation devices do not produce sensation 
during stimulation (ie, microcurrent therapy). Blinding 
can be monitored by asking participants whether they 
believed that ‘…the device was functioning properly?’.39 
Bennett et al37 also found that aspects of fidelity may 
contribute to underestimation of TENS effects including 
inadequacy of TENS technique; inadequate dosing; and 
the effect of concurrent analgesia in placebo groups.37
Why it is important to do this review
The debate about the clinical efficacy of TENS for the 
relief of pain in adults has been ongoing since TENS was 
introduced in the early 1970s. The majority of systematic 
reviews published to date have been inconclusive, despite 
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a vast number of published RCTs. This has resulted in 
contradictory recommendations from clinical guideline 
panels. For example, the National Institute of Health 
and Care Excellence recommends that TENS should be 
offered as an adjunct to core treatment for osteoarthritis40 
but not for non-specific chronic low back pain.41
Previous systematic reviews tend to focus on pain associ-
ated with specific medical conditions, in line with classical 
pathology-based categorisation of pain as a secondary 
outcome of the disease. This markedly reduces sample 
sizes of pooled data and the statistical power of the 
meta-analysis. In general, the findings of systematic reviews 
of the efficacy of TENS for specific medical conditions 
are inconclusive due to insufficient data. Methodological 
factors influencing estimates of efficacy include analyses 
used to measure treatment outcome, trial duration, with-
drawals and statistical imputation following withdrawal. 
Based on the work of Moore et al,42 the Pain, Palliative 
and Supportive Care group from Cochrane Collaboration 
suggest that trial arms with fewer than 200 participants in 
RCTs or fewer than 500 participants in meta-analyses are 
at a high risk of bias seriously undermining confidence in 
findings. To date, only two meta-analyses on TENS have 
come close to this threshold of acceptability and both 
found superiority over placebo (for acute postoperative 
pain14 and chronic musculoskeletal pain).35 Pooling data 
on pain intensity from RCTs irrespective of diagnostic 
condition would markedly improve the statistical power 
associated with meta-analyses of TENS. However, the 
inclusion of a wide variety of types of pain has the poten-
tial for increasing heterogeneity. The recent overview of 
Cochrane reviews on TENS for chronic pain published 
by the Cochrane Collaboration did not pool data and was 
inconclusive.29
The mechanism of action of TENS primarily involves 
neuromodulation of central nociceptive transmission 
irrespective of medical diagnosis. Therefore, TENS is 
used for symptomatic relief of pain rather than treat-
ment (cure) of pathology. The relationship between pain 
experience, response to treatment and pathology is vari-
able within and between individuals with similar condi-
tions. The pain experience is complex and influenced by 
contextual, social, psychological and biological factors. 
Traditionally, pain is evaluated from a pathology-based 
perspective and dichotomised into acute and chronic. 
Even when pain is attributed to a medical condition, the 
specifics of pathology driving an individual’s pain may be 
elusive. Sometimes pain does not fit into a classical pathol-
ogy-based category, as recognised by the WHO who intro-
duced a new phenomenological definition for chronic 
primary pain in the International Statistical Classification 
of Diseases and Related Health Problems (11th Revision, 
ICD-11).43 Moreover, pathophysiological processes do 
not dichotomise at specific time points, leading Loeser to 
suggest that the dichotomy of pain into acute and chronic 
should be abolished.44
There has been no convincing evidence that TENS 
outcome is affected by the nature of pathology, the type 
of pain or medical diagnoses.11 45 Thus, it seems logical to 
undertake a meta-analysis of the clinical efficacy of TENS 
by evaluating pain outcomes from a phenomenological 
perspective, irrespective of medical condition. This would 
increase statistical power and confidence in findings, 
and provide clinicians, policy-makers and patients with 
a source of information on the effects of TENS for any 
type of pain. We appreciate that there may be substantial 
differences in the context in which different types of pain 
are experienced (eg, acute vs chronic, negligible conse-
quence vs life-threatening and so on) and that this has the 
potential to generate clinical and statistical heterogeneity. 
Thus, concerns over an increase in clinical heterogeneity 
associated with combining different clinical conditions 
will be offset by conducting subgroup analyses of specific 
medical conditions based on ICD-11 categories if suffi-
cient data are available.
Aim
The aim of this systematic review with meta-analysis is 
to evaluate the clinical efficacy and safety of TENS for 
any type of acute and chronic pain in adults. The review 
protocol has been adapted from a Cochrane review 
on TENS for fibromyalgia previously published by the 
investigators.46
METHOdS
The protocol is reported in compliance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses Protocols (PRISMA) guidelines. The completed 
checklist can be found in the online supplementary mate-
rial (Table S1).
Patient and public involvement
There is no direct patient or public involvement in this 
study. Patients were not involved in the development 
of the research question and outcome measures or 
the design of the systematic review. Patients will not be 
involved with the conduct of the systematic review.
Criteria for considering studies for this review
Types of studies
We plan to include RCTs of TENS treatment for acute or 
chronic pain of any origin. We will exclude studies that 
were non-randomised, case reports and clinical observa-
tions. We plan to include parallel group and crossover 
trial designs. We plan to include single treatment inter-
ventions without follow-up. However, we will conduct a 
subgroup analysis of RCTs that delivered at least 2 weeks 
of treatment and had a duration of at least 8 weeks as 
these are considered as best practice. We require a full 
journal publication of a full trial report. We will not 
include, online clinical trial results, summaries of other-
wise unpublished clinical trials, abstracts or letters.
Types of participants
We will include RCTs of adult participants aged ≥18 years 
with any type of clinical pain.
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Types of TENS interventions
We will include all RCTs that administered TENS as 
non-invasive electrical stimulation of the skin with the 
intention of stimulating peripheral nerves to alleviate 
pain using a standard TENS device.11
Non-invasive
We will only include RCTs that administered TENS across 
the intact surface of the skin using surface electrodes. 
We will exclude invasive nerve stimulation techniques 
such as percutaneous electrical nerve stimulation and 
electroacupuncture.
Type of TENS device
We will only include RCTs that administered TENS using 
a standard TENS device,11 regardless of the device manu-
facturer, that delivered biphasic or monophasic pulsed 
electrical currents. We will exclude RCTs that admin-
istered ‘TENS-like’ currents that are not typical output 
specifications of a standard TENS device.11 We will 
exclude neuromuscular electrical stimulation (NMES) 
devices, interferential current devices and microcurrent 
devices.11 We will exclude TENS delivered using single 
probe electrodes (ie, TENS pens) or using matrix elec-
trodes and electrode arrays.
TENS technique
We will include RCTs that used a standard TENS device 
irrespective of the term to describe the type of TENS tech-
nique (eg, conventional TENS, acupuncture-like TENS, 
high-frequency-low-intensity, low-frequency-high intensity 
and so on). We will exclude RCTs that did not use pulsed 
electrical currents. We will only include RCTs that admin-
istered TENS on areas of the body that were sensate, and 
where electrodes were located at (a) the site of pain or 
(b) over nerve bundles proximal (or near) to the site 
of pain. We will include TENS delivered at acupuncture 
points only if the point was lying over nerve bundles prox-
imal (or near) to the site of pain. We will include all RCTs 
irrespective of the current amplitude of TENS and/or 
participant-reported TENS intensity. We consider partici-
pant-reported strong but comfortable TENS sensations as 
optimal and will conduct a subgroup analysis to compare 
TENS at intensities described as ‘strong’ (optimal) versus 
those described as ‘mild’, ‘faint’ or ‘barely perceptible’ 
(suboptimal). We will include RCTs that delivered TENS 
at intensities reported to generate muscle twitches 
providing TENS was administered using a standard TENS 
device with the primary goal to alleviate pain. We will only 
include RCTs that delivered pulse frequencies of TENS 
that were <250 pulses per second and pulse durations 
<1 ms. We will include any type of pulse pattern.
Dosage and regimen
We will include RCTs that administered TENS for any 
duration or regularity of treatment. We will include TENS 
that was administered by a therapist and/or self-adminis-
tered by study participants.
Evaluation of TENS treatment effects
We will include TENS administered as a sole treatment 
or in combination with usual care and/or other treat-
ments. We will exclude RCTs where it was not possible to 
isolate the effects of TENS from other treatments. We will 
include RCTs that evaluate TENS versus
 ► Placebo TENS (eg, sham (no current) TENS device).
 ► No treatment or waiting list control.
 ► Standard of care.
 ► Another treatment, both pharmacological and 
non-pharmacological.
We will include two TENS interventions from the same 
RCT. To avoid ‘double-counting’ and unit-of-analysis 
errors, we will not enter several interventions versus one 
comparison group in common (eg, placebo TENS) into 
the same meta-analysis. We will follow recommendations 
from Cochrane to combine TENS intervention groups to 
create a single pairwise comparison unless one or more 
of the TENS interventions do not meet our criteria for 
optimal TENS technique as described in the section 
TENS technique. In such situations, we will select one 
TENS intervention that meets the criteria for optimal 
technique.
Criteria and credibility of placebo TENS
The credibility and blinding of placebo TENS is an issue 
in TENS studies as it is not possible to blind participants to 
TENS sensation, although it is possible to generate uncer-
tainty about allocation to active and inactive TENS.39 We 
define a sham TENS device as a device similar in appear-
ance to the real TENS device used in the study but where 
the current output was modified so that there is no elec-
trical current, or a barely perceptible electrical current 
and/or electrical current that ceases within 1 min.16 38 We 
will identify RCTs that attempt to assess the credibility of 
placebo TENS and will conduct a subgroup analysis of 
RCTs that judge the intervention to be a credible placebo 
TENS.
Search methods for identification of studies
The systematic review process will be guided by the 
Cochrane Collaboration of Systematic Reviews47 and the 
PRISMA statement.48
We will conduct a literature search to identify RCTs 
published from the date of inception of the database 
(online supplementary material - Appendix 1) and screen 
them against our eligibility criteria for inclusion in our 
review. The purpose of the search is to provide compre-
hensive coverage of a wide variety of pain conditions (eg, 
ICD-11 categories) at various stages and settings (eg, 
acute, chronic, palliative, community, primary, secondary 
and tertiary). Also, we will conduct a literature search to 
identify systematic reviews published from inception and 
will harvest RCTs to gain insights into the consistency of 
RCTs included across systematic reviews of similar condi-
tions, including our own (online supplementary material 
Appendix 2). There is no intention to evaluate or quality 
assess previously published systematic reviews.
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Electronic searches
We will search the following electronic databases using 
a combination of controlled vocabulary, that is, medical 
subject headings (MeSH) and free-text terms to identify 
published RCTs and systematic reviews from inception to 
the date of the search.
 ► Cochrane Library (CENTRAL).
 ► MEDLINE (via PubMed).
 ► Embase (via OVID).
 ► CINAHL (via EBSCO).
 ► PsycINFO (via EBSCO).
 ► LILACS (via Birme).
 ► PEDRO.
 ► Web of Science.
 ► AMED (via OVID).
 ► SPORTDiscus (via EBSCO).
We will tailor searches to the individual databases by 
adapting the MEDLINE search strategy for the other data-
bases listed. There will be no language restrictions and we 
will identify all relevant RCTs irrespective of language and 
will translate articles where required.
data collection and analysis
Selection of studies
Two review authors will independently screen records 
to identify RCTs. We will remove duplicates and elim-
inate records that clearly do not satisfy the inclusion 
criteria. Full-text reports of potentially eligible RCTs will 
be obtained and screened for eligibility by two review 
authors. Also, two review authors will screen records to 
identify systematic reviews on TENS and will read full-text 
reports to create a list of RCTs included in each system-
atic review. Disagreements at any stage of the process 
will be resolved by consensus using a third review author 
as arbiter. We will not anonymise records of systematic 
reviews or RCTs in any way before assessment. We will 
create a PRISMA flowchart.47 48
Data extraction and management
Two review authors will extract data from included RCTs 
independently and will check for agreement before 
entering into a software. Disagreement will be resolved 
by consensus with a third author acting as arbiter. We 
will include information about study design, study partic-
ipants, sample size and interventions used. We will use 
these data to populate a ‘Characteristics of included 
RCTs’ table (online supplementary material Appendix 3). 
We will contact authors via email to clarify issues relating 
to inclusion, risk of bias and missing data.
Types of outcome measures
We will include RCTs that measure pain using stan-
dard subjective scales (numerical rating scale or visual 
analogue scale (VAS)) for pain intensity or pain relief, or 
both. We will include measures of pain at rest and pain 
on movement. We will extract pain measures assessed 
using condition-specific questionnaires (eg, Western 
Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC), Fibromyalgia Impact Questionnaire 
(FIQ)). We plan to extract outcome measurement data 
before, during and after the intervention, where data 
are available. We plan to extract data on clinical status or 
health-related quality of life and treatment satisfaction. 
We will capture data for adverse effects of any type or 
severity as descriptions from participants and number 
of withdrawals and/or stopping of treatment. Serious 
adverse events are defined as untoward medical occur-
rence or effect resulting in death, threat to life, hospi-
talisation, significant disability or incapacity, congenital 
anomaly or birth defect.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk 
of bias for each study, using the criteria outlined in the 
Cochrane Handbook for Systematic Reviews of Interven-
tions.47 Risk of bias assessment consists of the assessment 
of selection bias, attrition bias, blinding and sample size 
(online supplementary material Appendix 4).
Measures of treatment effect
Pain outcomes tend to have a U-shaped distribution 
with some patients experiencing substantial reduc-
tions in pain and others experiencing minimal or no 
improvement.49 Thus, data expressed as averages may be 
misleading as a small average between-group effect size 
may represent a proportion of participants that actually 
responded very well to the intervention.50 We do not 
know whether outcomes are bi-modally distributed in 
trials of TENS but we expect most RCTs in this review to 
present effect sizes as the average between intervention 
groups. There is little consensus or evidence regarding 
what the threshold should be for a clinically important 
difference in pain intensity based on the between-
group difference during or after the intervention. The 
Outcome Measures in Rheumatology (OMERACT 12)51 
group states that the proportion of patients achieving 
one or more thresholds of improvement from baseline 
pain should be reported in addition to mean change. 
We will follow the Initiative on Methods, Measurement, 
and Pain Assessment in Clinical Trials (IMMPACT) 
definitions when analysing response to treatment and 
consider reports of pain relief of ≥30% compared with 
baseline as responders.52
Primary outcomes
Proportion of participant-reported pain relief of >30% expressed 
as frequency (dichotomous) data
Our primary outcome is the responder rate. The propor-
tion of participants reporting pain relief of ≥30% (ie, at 
least moderate pain relief) compared with baseline in each 
group will be classed as responders.49 53 We will calculate 
risk ratio and risk difference with 95% CIs. Comparisons 
between groups will then be finalised by calculating the 
number needed to treat to benefit (NNTB) as an absolute 
measure of treatment effect where possible.52
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Participant-reported pain intensity expressed as mean (continuous) 
data
We intend to calculate the mean difference (MD) with 
95% CI for continuous data collected on identical scales. 
We intend to calculate the standardised MD with 95% CI 
for continuous data collected on different scales. We 
intend to use a between-group difference of ≥10 mm 
on a 0–100 mm VAS for a minimally important outcome 
for pain intensity. We will interpret these findings with 
caution as it remains possible that estimates that fall 
close to this point may reflect a treatment that benefits 
an appreciable number of patients. In addition, we will 
calculate the difference between groups in the percentage 
change in pain intensity during treatment relative to base-
line. This will enable us to classify according to IMMPACT 
criteria for clinically important change, as previously used 
in Cochrane reviews, where no important change <15%, 
minimally important change 15%>30%, moderately 
important change 30%>50% and substantially important 
change ≥50%.52
Secondary outcomes
 ► Proportion of participants reporting pain relief of 
≥50% (ie, at least substantial pain relief).
 ► Participant-reported condition-specific pain-related 
outcomes (eg, WOMAC and FIQ).
 ► Participant-reported clinical status or health-related 
quality of life, including activities of daily living and 
fatigue, using any validated tool (eg, Patient Global 
Impression of Change (PGIC), Short-Form Health 
Survey (SF-36), EuroQol instruments).
 ► Participant-reported treatment satisfaction.
 ► Participant-reported adverse events expressed as 
frequency (dichotomous) data and/or severity.
Dichotomous and continuous data will be analysed using 
the same procedures described for primary outcomes. For 
health-related quality of life data, we intend to consider a 
difference >10% of the scale employed to be minimally 
important.54
Unit-of-analysis issues
We will include crossover designs but intend only to enter 
the first period data into the meta-analysis. If this was not 
reported, we will note this and not include the data. If 
data is reported appropriately then we intend to include 
the data using the generic inverse variance feature.
Dealing with missing data
An intention-to-treat (ITT) analysis will be used when 
the ITT population were randomised, received at least 
one dose of TENS, and provided at least one postbase-
line outcome measurement. Missing participants will be 
assigned zero improvement wherever possible.
Assessment of heterogeneity
We will examine heterogeneity using visual inspection of 
forest plots, L'Abbé Plots,55 the I² statistic and the χ2 test, 
if appropriate.56 We will use the Cochrane Collaboration’s 
rough guide to interpretation as not important (0%–40%), 
moderate (30%–60%), substantial (50%–90%) and 
considerable (75%–100%). We will use a random-effects 
model as the studies are anticipated to be heterogeneous. 
This accounts for heterogeneity among study results 
beyond the variation associated with the fixed-effects 
model. Sources of heterogeneity will be investigated with 
subgroup analysis and/or a random-effects meta-regres-
sion analysis. We anticipate that causes of heterogeneity 
may be: clinical condition, acute versus chronic pain, 
and optimal versus suboptimal TENS. All analyses will be 
conducted contingent on data availability.57
Assessment of reporting biases
Publication bias will be assessed using a method designed 
to detect the amount of unpublished data with a null effect 
required to make any result clinically irrelevant (usually 
taken to mean an NNTB of 10).58 The influence of small 
study samples will be assessed using the risk of bias crite-
rion ‘study size’. We plan to visually inspect funnel plots 
to explore the likelihood of reporting biases if there are 
at least 10 RCTs in a meta-analysis and if RCTs differed in 
sample size. We will use Egger test to detect small study 
bias for RCTs using continuous outcomes.47
Data synthesis
We will pool data using Review Manager59 and will under-
take meta-analyses of outcome data using a random-ef-
fects model. We will group data according to outcome 
and measurement time points as: (i) during stimula-
tion or immediately after stimulation at each treatment 
session, or both; and (ii) postintervention follow-up at 
<2 weeks postintervention (short term), 2–7 weeks postin-
tervention (mid-term), and ≥8 weeks postintervention 
(long term).
We plan to undertake a narrative synthesis if data are 
inadequate to support statistical pooling.
Quality of the evidence
We consider single RCTs too imprecise unless the sample 
size is >400 participants for continuous data and >300 
events for dichotomous data. We will present the outcome 
of the ‘Risk of Bias’ assessments in the reporting. We 
consider pooled data to be imprecise unless the sample 
size for a treatment arm is >500 participants. We will 
present pooled effects for outcomes with Grades of 
Recommendation,Assessment, Development and Eval-
uation (GRADE) judgements in ‘Summary of findings’ 
tables. Two review authors will independently rate the 
quality of outcomes using the GRADE system (GRADEpro 
GDT 2015, online supplementary material Appendix 5).
Subgroup analysis
We plan to undertake subgroup analyses for acute versus 
chronic pain and for specific painful conditions. We also 
plan to conduct subgroup analyses to investigate the 
possible impact of TENS technique on analgesic efficacy 
as follows:
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 ► Optimal intensity described as ‘strong’ versus subop-
timal intensity described as ‘barely perceptible’, 
‘'faint’, or ‘mild’.
 ► Conventional TENS versus acupuncture-like TENS.
 ► Assessment during TENS versus after TENS.
 ► TENS administered as a sole treatment versus TENS 
administered in combination with other treatments.
 ► TENS administered as a single dose versus repetitive 
dose.
Postsubgroup analysis, we contemplate conducting a 
network meta-analysis contingent on meeting transitivity 
assumption.
Sensitivity analysis
We plan to analyse the effect of excluding RCTs with a 
high risk of bias.
Ethics and dissemination
This systematic review will not use data from individual 
participants to protect privacy, and the results will 
be disseminated in a peer-reviewed publication and 
presented at a scientific conference.
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